Cabotegravir Pellet Implant with Levonorgestrel
CAB + LNG Pellet
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Subdermal
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): CONRAD
Details
- API: Not Yet Finalized - Multiple API Combinations Tested
- Target: Progesterone Receptor
-
Mechanism of Action:
- Endometrial Changes
- Cervical Mucus Changes
- Inhibition of Sperm Motility
- Anti-Microbial
- Ovulation Inhibition
- Inactive Materials: Not Yet Determined
- Regimen: 1 Insertion/6-12 Months
- MPT: Potential MPT
- Promising Attributes: The method offers both pregnancy prevention and HIV prevention, it is small in size, bioresorbable so there is no need for removal, and will be administered with a user-friendly inserter.
Product Status
Recent Pre-Clinical Research. Research was funded by USAID through the MATRIX drug development program, which was terminated in 2025. Record will be monitored for potential status change to inactive.
History
During a MATRIX investigator meeting in 2023, it was reported that current optimization studies are evaluating coated LNG pellets with reduced loading and testing lead CAB + LNG pellets in rats. CONRAD has evaluated multiple API combinations in their bioabsorbable pellet implant system, for which they have developed a universal inserter.